EuxanthoneCAS# 529-61-3 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 529-61-3 | SDF | Download SDF |
| PubChem ID | 5281631 | Appearance | Yellow powder |
| Formula | C13H8O4 | M.Wt | 228.2 |
| Type of Compound | Xanthones | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1,7-dihydroxyxanthen-9-one | ||
| SMILES | C1=CC2=C(C(=C1)O)C(=O)C3=C(O2)C=CC(=C3)O | ||
| Standard InChIKey | KDXFPEKLLFWHMN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C13H8O4/c14-7-4-5-10-8(6-7)13(16)12-9(15)2-1-3-11(12)17-10/h1-6,14-15H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Euxanthone has vasorelaxation effect, may be through multiple pathways involved PKC-mediated signal pathway and calcium-independent pathway, it induces its vasodilator effect through inhibition of calcium-sensitive mechanisms activated by protein kinase C. Euxanthone-induced neurite outgrowth was actively regulated by transcription factor E2F-5 via PKC pathway, it-induced differentiation of the neuroblastoma BU-1 cells may be mediated through the differential expression of PKC-alpha, -beta, -delta, -lambda and -zeta isoforms. |
| Targets | NO | PKC | Calcium Channel | Akt |
| In vitro | Vasorelaxant effect of euxanthone in the rat thoracic aorta.[Pubmed: 16678494]Vascul Pharmacol. 2006 Aug;45(2):96-101.This study was undertaken to investigate the effect of Euxanthone on isolated rat thoracic aorta. Expression of protein kinase C isoforms in euxanthone-induced differentiation of neuroblastoma cells.[Pubmed: 11488451]Planta Med. 2001 Jul;67(5):400-5.Euxanthone, a potent neuritogenic compound isolated from the roots of the medicinal herb Polygala caudata, has recently been shown to induce the differentiation of murine neuroblastoma Neuro 2A (BU-1) cells. |
| Kinase Assay | Differential activation of protein kinase C isoforms by euxanthone, revealed by an in vivo yeast phenotypic assay.[Pubmed: 12451499]Involvement of protein kinase C and E2F-5 in euxanthone-induced neurite differentiation of neuroblastoma.[Pubmed: 16546434]Mechanism of the vasodilator effect of Euxanthone in rat small mesenteric arteries.[Pubmed: 20097048]Phytomedicine. 2010 Jul;17(8-9):690-2.In the present work we investigated the mechanism involved in the vasodilator effect induced by Euxanthone in rat small mesenteric arteries.
Int J Biochem Cell Biol. 2006;38(8):1393-401.Euxanthone, a neuritogenic agent isolated from the medicinal herb Polygala caudata, has been shown to induce morphological differentiation and neurite outgrowth in murine neuroblastoma Neuro 2a cells (BU-1 subclone). In order to elucidate the underlying mechanisms of Euxanthone-induced neurite outgrowth, a proteomic approach was employed. Planta Med. 2002 Nov;68(11):1039-41.
|
Euxanthone Dilution Calculator
Euxanthone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.3821 mL | 21.9106 mL | 43.8212 mL | 87.6424 mL | 109.553 mL |
| 5 mM | 0.8764 mL | 4.3821 mL | 8.7642 mL | 17.5285 mL | 21.9106 mL |
| 10 mM | 0.4382 mL | 2.1911 mL | 4.3821 mL | 8.7642 mL | 10.9553 mL |
| 50 mM | 0.0876 mL | 0.4382 mL | 0.8764 mL | 1.7528 mL | 2.1911 mL |
| 100 mM | 0.0438 mL | 0.2191 mL | 0.4382 mL | 0.8764 mL | 1.0955 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Genistin
Catalog No.:BCN2396
CAS No.:529-59-9
- Prunin
Catalog No.:BCN5693
CAS No.:529-55-5
- Scutellarein
Catalog No.:BCN5380
CAS No.:529-53-3
- Azaleatin
Catalog No.:BCN8207
CAS No.:529-51-1
- Gentisein
Catalog No.:BCN3356
CAS No.:529-49-7
- Myricetin
Catalog No.:BCN5692
CAS No.:529-44-2
- Ombuin
Catalog No.:BCN5691
CAS No.:529-40-8
- Chamazulene
Catalog No.:BCC8145
CAS No.:529-05-5
- 20-Hydroxyecdysone
Catalog No.:BCN5688
CAS No.:5289-74-7
- Olean-12-ene-3,11-diol
Catalog No.:BCN5686
CAS No.:5282-14-4
- Cearoin
Catalog No.:BCN7772
CAS No.:52811-37-7
- Dalbergiphenol
Catalog No.:BCN7451
CAS No.:52811-31-1
- 6,7-Dihydroxy-4-Methylcoumarin
Catalog No.:BCC8287
CAS No.:529-84-0
- Motilin (human, porcine)
Catalog No.:BCC5894
CAS No.:52906-92-0
- PRIMA-1MET
Catalog No.:BCC2414
CAS No.:5291-32-7
- Dammaradienyl acetate
Catalog No.:BCN5689
CAS No.:52914-31-5
- Neosophoramine
Catalog No.:BCN5690
CAS No.:52932-74-8
- Nanaomycin A
Catalog No.:BCC3611
CAS No.:52934-83-5
- N-(2,6-Diphenylmethyl)-1-piperazine acetylamine
Catalog No.:BCC9052
CAS No.:5294-61-1
- Genz-644282
Catalog No.:BCC1592
CAS No.:529488-28-6
- Ajugol
Catalog No.:BCN2883
CAS No.:52949-83-4
- Acetylisocupressic acid
Catalog No.:BCN5695
CAS No.:52992-82-2
- Prednisone
Catalog No.:BCC4957
CAS No.:53-03-2
- Estrone
Catalog No.:BCN2201
CAS No.:53-16-7
Involvement of protein kinase C and E2F-5 in euxanthone-induced neurite differentiation of neuroblastoma.[Pubmed:16546434]
Int J Biochem Cell Biol. 2006;38(8):1393-401.
Euxanthone, a neuritogenic agent isolated from the medicinal herb Polygala caudata, has been shown to induce morphological differentiation and neurite outgrowth in murine neuroblastoma Neuro 2a cells (BU-1 subclone). In order to elucidate the underlying mechanisms of Euxanthone-induced neurite outgrowth, a proteomic approach was employed. In the present study, two dimensional (2-D) gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) mass spectrometry were performed to investigate the alterations in protein expression profile of Euxanthone-treated BU-1 cells. Fourteen identified proteins were changed in expression levels after induction of neurite growth. These proteins included participants in transcription and cell cycle regulation, calcium influx and calcium signaling, fatty acid metabolism, cytoskeleton reorganization, casein kinase signal transduction, putative transbilayer amphipath transport and protein biosynthesis. Among the 14 identified proteins, E2F transcription factor 5 (E2F-5) was significantly up-regulated after Euxanthone treatment. Go6976, a protein kinase C (PKC) alpha/betaI inhibitor, was found to inhibit neuritogenesis and expression of E2F-5 in the Euxanthone-treated BU-1 cells, while SH-6, the Akt/PKB inhibitor, had no inhibitory effect. The gene silencing of E2F-5 by small interfering RNA (siRNA) was found to abolish the Euxanthone-induced neurite outgrowth. In conclusion, these results indicated that the transcription factor E2F-5 was actively involved in the regulation of Euxanthone-induced neurite outgrowth via PKC pathway.
Differential activation of protein kinase C isoforms by euxanthone, revealed by an in vivo yeast phenotypic assay.[Pubmed:12451499]
Planta Med. 2002 Nov;68(11):1039-41.
The protein kinase C (PKC) modulatory effects of Euxanthone, isolated from the wood of Cratoxylum maingayi, on isoforms alpha, betaI, delta, eta and zeta were characterised using an alternative in vivo yeast phenotypic assay. The present study shows that Euxanthone can activate isoforms alpha, betaI, delta, eta and zeta, being more effective on PKC-betaI, -delta, -eta and -zeta than the established PKC activators used (the phorbol ester PMA and arachidonic acid for PKC-zeta). Furthermore, Euxanthone presents differences on its potency towards individual PKC isoforms, showing a remarkable selectivity for PKC-zeta. These results can help to clarify the molecular basis of the Euxanthone-mediated effects.
Mechanism of the vasodilator effect of Euxanthone in rat small mesenteric arteries.[Pubmed:20097048]
Phytomedicine. 2010 Jul;17(8-9):690-2.
In the present work we investigated the mechanism involved in the vasodilator effect induced by Euxanthone in rat small mesenteric arteries. We observed that Euxanthone induced concentration-dependent vasodilatation in arteries by a mechanism independent on the release of endothelial factors, such as nitric oxide (NO) and cyclooxygenase-derived factors. In addition our results also suggest that Euxanthone induced its vasodilator effect through inhibition of calcium-sensitive mechanisms activated by protein kinase C, rather than by inhibition of contractions dependent on the release of the intracellular calcium stores or by inhibition of voltage-operated calcium channels.
Vasorelaxant effect of euxanthone in the rat thoracic aorta.[Pubmed:16678494]
Vascul Pharmacol. 2006 Aug;45(2):96-101.
This study was undertaken to investigate the effect of Euxanthone on isolated rat thoracic aorta. Euxanthone concentration-dependently relaxed high K+-induced sustained contractions with IC50 values of 32.28+/-1.73 microM and this inhibition was antagonized by increasing the Ca2+ concentration in the medium. These results indicated that Euxanthone may have calcium antagonistic property. Euxanthone also relaxed norepinephrine (NE)-induced sustained contractions with IC50 values of 32.50+/-2.15 microM and this relaxant effect was unaffected by the removal of endothelium or by the presence of propranolol, indomethacin, glibenclamide or N(omega)-nitro-L-arginine. Moreover, Euxanthone inhibited both the phasic and tonic contractions induced by NE in a concentration-dependent manner and showed more potent inhibition on phasic contraction (P < 0.01). Pre-treatment with Euxanthone inhibited vascular contraction induced by phorbol 12, 13-dibutyrate (PDBu), a protein kinase C (PKC) agonist, in either the presence or absence of Ca2+ in the solution with IC50 values of 20.15+/-1.56 and 18.30+/-1.62 microM, respectively. However, when the tissues were treated with Euxanthone after the PDBu-induced contraction had reached a steady state, the tension was not affected by Euxanthone. This study also showed that the inhibitory effect of pre-treatment of Euxanthone was more potent than the post-treatment after the tension had reached a steady state. These results suggested that the vasorelaxation of Euxanthone may be through multiple pathways involved PKC-mediated signal pathway and calcium-independent pathway besides the direct inhibition of calcium influx and its vasorelaxant effect is more active on calcium-independent pathway and more sensitive to the initial stage of contraction.
Expression of protein kinase C isoforms in euxanthone-induced differentiation of neuroblastoma cells.[Pubmed:11488451]
Planta Med. 2001 Jul;67(5):400-5.
Euxanthone, a potent neuritogenic compound isolated from the roots of the medicinal herb Polygala caudata, has recently been shown to induce the differentiation of murine neuroblastoma Neuro 2A (BU-1) cells. In this study, the role of protein kinase C (PKC) and the expression of various PKC isoforms in Euxanthone-treated BU-1 cells were examined. mRNA phenotyping using the reverse-transcription polymerase chain reaction (RT-PCR) showed that BU-1 cells express six different PKC isoforms, namely PKC-alpha, -beta, -delta, -epsilon, -lambda, and -zeta. Differential regulation and expression of PKC isoforms was observed in BU-1 cells treated with 100 microM Euxanthone. PKC-apha, -beta, -delta, -lambda and -zeta were all up-regulated, with 1.7- to 9.5-fold increase, at around 30 to 60 minutes after Euxanthone treatment. The expression level of PKC-epsilon remained relatively constant during the treatment. PKC-gamma, -eta, and -theta were not detected in both untreated and Euxanthone-treated BU-1 cells. Staurosporine, a broad spectrum PKC inhibitor, was found to inhibit both spontaneous and Euxanthone-induced neuritogenesis in BU-1 cells. A significant reduction of the Euxanthone-induced neuritogenic effect was also observed when the PKC isoform-specific inhibitor Go6976 was included in the culture. These results suggest that the Euxanthone-induced differentiation of the neuroblastoma BU-1 cells may be mediated through the differential expression of PKC-alpha, -beta, -delta, -lambda and -zeta isoforms.
